Programme

Thursday, 24th June
07:00	Welcome Address Main Arena
07:10	Session 1: Future trends in Management of Ischaemic Stroke Has the supremacy of Endarterectomy finally been proven?
	Level One Evidence: Are Rcts Applicable To Contemporary Carotid Practice?
07:10	Carotid Revascularisation Endarterectomyversus Stenting Trial (CREST) » Frank Veith (New York University School of Medicine, New York, USA)
07:15	Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS) and the International Carotid Stenting Study (ICSS) » Sumaira MacDonald (Freeman Hospitals, Newcastle, UK)
07:20	Latest Results form the ASCTII Trial » Kazem Rahimi (St George's Hospital, London, United Kingdom), Alison Halliday (St George's Hospital, London, United Kingdom)
07:25	How to interpret the CAS versus - CEA results, an updated metanalysis » Jan Brunkwall (University of Cologne, Cologne, Germany)
	Debate 1:
07:30	CAS offers longterm benefit and restenosis rates which are comparable to CEA » Klaus Mathias (Direktor der Radiologischen Klinik, Klinikum Dortmund, Germany)
07:35	CAS is plagued with short term risks in the absence of proven long term benefit: It is not worth the risk » Mohan Adiseshiah (University College London, London, United Kingdom)
07:40	-- Audience Vote --
	Debate 2:
07:42	Carotid Endarterectomy provides life-long stroke protection in "high-risk" medical patients » Carlos H Timaran (University of Texas Southwestern Medical School, Dallas, Texas)
07:47	Is CEA financially viable in patients at high medical risk? Do they live to experience the benefits » Mark D Morasch (Northwestern Memorial Hospital, Chicago, Illinois, USA)
07:52	-- Audience Vote --
	Debate 3:
07:54	CEA is the procedure of choice for Stroke in evolution. Treatment by CAS is akin to playing Russian Roulette » Sherif Sultan (Western Vascular Institute)
08:01	CAS is safe and should be the treatment of choice when urgent carotid revascularisation is needed » John Kakisis (Athens University Medical School, Athens, Greece), Christos Liapis (Athens University Medical School, Athens, Greece)
08:06	-- Audience Vote --
	Debate 4:
08:08	Screening for Carotid Artery Disease is a futile endeavor and waste of money. There is no evidence to suggest that CEA or CAS are warranted in asymptomatic patients » Frank Veith (New York University School of Medicine, New York, USA)
08:13	Carotid Screening is warranted: An analysis of the 3.1 million patients screened for carotid disease and a paradigm for deciding who should be screened for carotid stenosis » Craig Kent (University of Wisconsin School of Medicine & Public Health, Madison, USA)
08:18	-- Audience Vote --
08:20	-- Panel Sum-up --
	Clinical Insight
08:25	Carotid artery stenting for post-carotid endarterectomy restenosis is safer than redo carotid endarterectomy and should be the procedure of choice » Peter Lawrence (Gonda Vascular Center, Los Angeles, California, USA)
	A Look To The Future
08:30	Update on the vulnerable carotid plaque. A bioengineering evaluation of real-life patients » Caitriona Lally (DCU)
08:35	Duplex-assisted internal carotid artery balloon angioplasty and stent placement » Enrico Ascher (Mount Sinai School of Medicine, New York, New York, USA), Anil Hingorani (College of Medicine, SUNY Brooklyn, Brooklyn, New York)
08:55	Session 2: Hybrid techniques & Management of Thoracic Aortic Pathology Level One Evidence, debates and controversies in real-life clinical practice and an introduction uo new techniques and device innovation
	Level One Evidence
08:55	The dilemma of the Instead trial. One arm monotechnology is not enough. » Klaus Mathias (Direktor der Radiologischen Klinik, Klinikum Dortmund, Germany)
	Debate 1:
09:00	TEVAR is the best option for ruptured TAA » Venkatesh Ramaiah (ARIZONA HEART INSTITUTE, USA.)
09:05	Open Repair remains the gold standard for ruptured TAA » Hazim Safi (Memorial Hermann Hospital, Houston, Texas)
09:10	-- Audience Vote --
	Debate 2:
09:12	Contemporary Outcomes of TEVAR: Current Devices are broadly applicable to all pathologies » Mark Eskandari (Northwestern Memorial Hospital, Chicago, Illinois, USA)
09:17	Pathological specific devices are essential otherwise we risk doing more harm than good. Unique insight form the European registry on endovascular aortic repair complications (Retrograde ascending aortic dissection during or after thoracic aortic stent graft placement) » Fotis Markatis (Laikon Hospital, University of Athens, Athens, Greece)
09:22	-- Audience Vote --
	Debate 3:
09:24	Penetrating aortic ulcers (PAU) and intramural hematoma (IMH): New insights and treatment guidelines. Endovascular Repair is not always the best option » Frank Criado (Union Memorial/MedStar Health)
09:29	Penetrating aortic ulcers and intramural hematomas: endovascular management is the only course of action » Vincent Riambau (University of Barcelona, Hospital Clinic, Barcelona, Spain)
09:34	-- Audience Vote --
	Debate 4:
09:36	Once dissected always dissected. Stent graft repair is seldom indicated and Medical Therapy is still the best option for chronic type B dissection » Alan Lumsden (Methodist DeBakey Heart and Vascular Center)
09:41	Endovascular intervention has lowered the risk of intervention and is currently the best treatment option for chronic type B dissection » Rodney A White (UCLA School of Medicine, Los Angeles, California)
09:46	-- Audience Vote --
	Debate 5:
09:48	Endovascular technology will overcome current device limitations in type A aortic dissection » Ian Loftus (St George's Hospital, London, United Kingdom)
09:53	Primary open repair is the best solution for Type A Arotic Dissection. Endografts are doomed to failure for this indication » Hazim Safi (Memorial Hermann Hospital, Houston, Texas)
09:58	-- Audience Vote --
10:00	-- Panel Sum-up --
10:05	Mapping the aorta: A new look at anatomy in the era of endograft repair » Frank Criado (Union Memorial/MedStar Health)
	A Look To The Future
10:10	Next Generation Devices for TEVAR. What to expect next. » Mark Farber (University of North Carolina, Chapel Hill, North Carolina)
	Tips And Tricks
10:15	Complications and their management after TEVAR » W. Anthony Lee (Division of Vascular Surgery and Endovascular Therapy, Gainesville, Florida)
10:20	Tips and Tricks for Percutaneous TEVAR » Mark Eskandari (Northwestern Memorial Hospital, Chicago, Illinois, USA)
10:25	Coffee Break
11:00	Session 3: New Insights and On-going Contoversies in AAA Management An overview of the most recent randomized clinical trials, enthusiastic debates on unresolved issues in everyday clinical, and an insight into current innovation and future directions in abdominal aortic diagnosis and management.
	Level One Evidence
11:00	Two-year results of the OVER Trial » Frank A Lederle (VA Medical Center, Minneapolis, Minnesota, USA)
	Debate 1:
11:05	EVAR is the current gold standard for ruptured AAA: Opening a Ruptured AAA is murder! Results of a worldwide registry » Frank Veith (New York University School of Medicine, New York, USA)
11:10	There is no objective evidence to that EVAR improves outcome from rupture AAA. Open repair remains the proven standard of care » Martin Feeley (The Adelaide & Meath Hospital, Tallaght, Dublin )
11:15	-- Audience Vote --
	Debate 2:
11:17	Changes In Patient Fitness And EVAR Suitability During Surveillance Of Small AAAs: EVAR availability has lowered the threshold for small AAAs Repair? » Craig Kent (University of Wisconsin School of Medicine & Public Health, Madison, USA)
11:22	We still has no evidence to suggest that AAAs should be repaired at less than 5.5cm and are justified in withholding treatment while the aneurysm grows » Karl A Illig (University of Rochester, Rochester, New York, USA)
11:27	EVAR for small aneurysms: When to intervene » Brian Manning (Cork University College Hospital, Cork, Ireland)
11:32	-- Audience Vote --
	Debate 3:
11:34	The EVAR 2 debate was a whole lot of fuss over a very small issue: risk stratification of patients for endovascular AAA repair shows that the high risk group is quite small and helps to identify th » Craig Kent (University of Wisconsin School of Medicine & Public Health, Madison, USA)
11:39	Para Millennium High Risk AAA saga: A clinical dilemma but is not a major concern for the endovascular specialist! » Niamh Hynes (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
11:44	-- Audience Vote --
	Debate 4:
11:46	Bilateral Hypogastric revascularisation is not necessary. » Frank Veith (New York University School of Medicine, New York, USA)
11:51	Bilateral Hypogastric revascularisation is necessary to prevent long term complications and is relatively simple to perform with branched endografts. » Mark Farber (University of North Carolina, Chapel Hill, North Carolina)
11:56	-- Audience Vote --
	Debate 5:
11:58	Failed Endografts requiring open surgery can be safely left in situ » Brian Manning (Cork University College Hospital, Cork, Ireland)
12:03	Failed Endografts Requiring Open Surgery Mandate Graft Removal » Dieter Raithel (Medical Centre of Nuremberg, Nuremberg, Germany)
12:08	-- Audience Vote --
12:10	-- Panel Sum-up --
	Current Clinical Standards
12:15	SVS Clinical Practice Guidelines for AAA. Have they taught us something new? » Karl A Illig (University of Rochester, Rochester, New York, USA)
12:20	Are we looking in the wrong place: an analysis of 3.1 million patients screened for AAA with the proposal of a new system for identifying who should be screened for AAA disease » Craig Kent (University of Wisconsin School of Medicine & Public Health, Madison, USA)
12:25	Different guidelines are needed for men and women with AAA. Unique female behaviour » Marc R.h.m. Van Sambeek (Erasmus University & Catharina Hospital, Eindhoven, The Netherlands)
12:30	-- Panel Sum-up --
12:35	The Fascia suture technique as an alternative to classical cut down or closure device after EVAR » Jan Holst (Vascular Center Malmö-Lund, Malmö University Hospital, Malmö, Sweden.)
	A Look To The Future
12:40	Biomechanical Assessment of Rupture Potential for Abdominal Aortic Aneurysm » David Vorp (University of Pittsburgh, Pittsburgh, Pennsylvania, USA)
12:45	Computer-Aided Assessment of Abdominal Aortic Aneurysms » Tim McGloughlin (University of Limerick, Ireland.), Barry Doyle (University of Limerick, Ireland.)
12:50	The ever decreasing profile for EVAR: why is profile so important? » Mark Farber (University of North Carolina, Chapel Hill, North Carolina)
13:00	Lunch
14:00	Session 4: Redefining the Gold Standard for limb salvage Topical debates and innovative insights into current and future management of lower limb arterial occlusive disease
	Level One Evidence: Does It Live Up To The Real Clinical Test
14:00	The MIMIC trial does not apply to contemporary clinical practice » Mohan Adiseshiah (University College London, London, United Kingdom)
14:05	Total endovascular bypass: The Gore Viabahn system for long SFA occlusions » Jacques Bleyn (Antwerp Blood Vessel Center, Belgium)
	Debate 1:
14:10	Bypass is dead: Approaching six sigma perfection in endovascular procedures. Results of over 400 patients » Sam Ahn (University Vascular Associates and DFW Vascular Group, Dallas, Texas)
14:15	Bypass still plays a vital role in limb salvage » Peter Lawrence (Gonda Vascular Center, Los Angeles, California, USA)
14:20	-- Audience Vote --
	Debate 2:
14:22	Femoro-femoral cross-over bypass: a viable option in claudication » Vincent Riambau (University of Barcelona, Hospital Clinic, Barcelona, Spain)
14:27	Open surgery is no longer indicated beyond limb salvage. Our catheter skills have outshone our surgical prowess. Claudicants should never be treated with invasive surgery. » Jeffrey Indes (Yale University School of Medicine, New Haven, Connecticut, USA)
14:32	Trials of Peripheral Arterial Occlusive disease need a medical control. Medical therapy is still a viable option » Samuel Wilson (University of California, Irvine, California, USA)
14:37	-- Audience Vote --
	Debate 3:
14:39	In patients with multi-level occlusive disease it is not necessary to treat tibial arteries if inflow is adequate: Do no harm » Jerry Goldstone (University Hospitals Case Medical Center, Cleveland, Ohio, USA)
14:44	In multi-level occlusive disease the tibial arteries must be revascularised » Peter Faries (Mount Sinai School of Medicine, New York, New York, USA)
14:49	-- Audience Vote --
	Debate 4:
14:51	Tibial angioplasty is superior to bypass surgery » Peter A Schneider (Hawaii Permanente Medical Group, Honolulu, Hawaii)
14:56	Tibial angioplasty is still experimental: Bypass surgery remains the gold standard » Martin Feeley (The Adelaide & Meath Hospital, Tallaght, Dublin )
15:01	-- Audience Vote --
	Debate 5:
15:03	Multi-layer stents are the preferred option for popliteal aneurysm exclusion » Maria Antonella Ruffino (Western Vascular Institute)
15:08	Hybrid approach for treatment of behind the knee popliteal artery aneurysms » Anil Hingorani (College of Medicine, SUNY Brooklyn, Brooklyn, New York), Enrico Ascher (Mount Sinai School of Medicine, New York, New York, USA)
15:13	Bypass surgery is still the preferred option for popliteal aneurysm exclusion » Mohan Adiseshiah (University College London, London, United Kingdom)
15:18	-- Audience Vote --
15:20	-- Panel Sum-up --
	Current Clinical Standards
15:25	Are our practice guidelines outdated and who needs to be at the table when formulating a contemporary consensus? » Martin Feeley (The Adelaide & Meath Hospital, Tallaght, Dublin )
	Bioengineering Perspectives
15:30	Has the harnessing of spiral laminar flow been advantageous in clinical practice and what are the latest innovative developments in this area? » Peter A Stonebridge (Tayside Flow Technologies, Dundee, UK)
	Trainee Perspectives
15:35	Five Years Prospective study of Duplex Ultrasound Arterial Mapping (DUAM) as a primary modality in management of Critical lower limb ischemia (CLI). Technical and clinical outcome after Bypass Surgery (BS) and Endovascular Revascularisation (EvR) » Wael Tawfick (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
15:39	Methicillin resistant staphylococcal infections (MRSA) and colonisation rates and their consequences on long term upshots to Vascular patients imparting to a tertiary referral unit : a seven year expe » Kamsila Pillay (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
15:43	Supragenicular bypass using cuffed synthetic grafts in management of critical lower limb ischaemia (CLI): A 4 year observational parallel group prospective comparative study. » Wael Tawfick (Western Vascular Institute), Tayyab Mansoor Aslam (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
15:47	Session 5: Venous Forum Debates on the current best available treatmetns for venous disorders
	Venous Disease
	Debate 1:
15:47	Endovenous Laser Ablation: Wavelength and Fiber Innovation have ensured the superiority of Laser ablation over radiofrequency techniques » Lowell Kabnick (New York University School of Medicine, New York, USA)
15:52	Radiofrequency Ablation has less procedure related complications and is more effective in the long term than laser techniques » Mark H Meissner (University of Washington Medical Center, Seattle, Washington, USA)
15:57	Thermal ablation is a primitive way of managing superficial vein reflux » Sherif Sultan (Western Vascular Institute)
16:02	-- Audience Vote --
	Debate 2:
16:04	Pulmonary embolisation is correlated with location of DVTs. Not all Infraopopliteal DVTs are inert » Anil Hingorani (College of Medicine, SUNY Brooklyn, Brooklyn, New York)
16:09	Treatment of Infrapopliteal DVTs is an unnecessary waste of resources » Jerry Goldstone (University Hospitals Case Medical Center, Cleveland, Ohio, USA)
16:14	-- Audience Vote --
	Wound Care Management
16:16	Clinical applications of VAC. What can we learn from Bioengineering » Bauer Sumpio (Yale University School of Medicine, New Haven, Connecticut, USA)
16:21	Systematic Review: Does Topical Negative Pressure really heal wounds? » Stella Vig (St George's Hospital, London, United Kingdom)
16:26	Hyperbaric Oxygen Therapy is more clinically efficacious and cost effective compared to compression therapy in the treatment of chronic venous ulcers » Sherif Sultan (Western Vascular Institute), Wael Tawfick (Western Vascular Institute)
	Future Perspective
16:31	What lies ahead in the science of wound care? » Breda Cullen (Systagenix, UK)
	Trainee Perspectives
16:36	Case–control divergence of a Pivotal study of Tinzaparin alone versus Warfarin for treatment of Acute Deep Venous Thrombosis and Pulmonary Embolism. Early experience, Q-TWIST and paradigm shift in management of DVT in a tertiary referral centre » Nader Hamada (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
16:40	To ligate or not to ligate in migrating superficial thrombophlebitits » Muhammed Tubassam (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
16:44	Coffee Break
17:15	Session 6: Perspectives from the world of cardiology The latest developments and on-going controversies in the management of ischaemic and structural heart disease. Can we aplly this treatemtns to the vasculature in general?
	Structural Heart Disease
17:15	Aortic Valve repair: Transfemoral vs Transapical » Marc R.h.m. Van Sambeek (Erasmus University & Catharina Hospital, Eindhoven, The Netherlands)
17:20	Totally Percutaneous Aortic Valve Insertion » Brendan Gallagher (Director R&D, Medtronic, Galway, Ireland)
	Ischaemic Cardiac Disease
	Debate 1:
17:25	Drug-eluting stents are widely applicable the choice of drug is the only differential factor when treating the patient » Gary Ansel (Riverside Methodist Hospital, Columbus, Ohio, USA)
17:30	ASCERT: The American College of Cardiology Foundation-The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies. » Davide Capodanno (Ferrarotto Hospital, University of Catania, Catania, Italy)
17:35	New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery. » Bauer Sumpio (Yale University School of Medicine, New Haven, Connecticut, USA)
17:40	What happens to the femoral artery with manual compression hemostasis? Do we really know? » Dusan Pavcnik (Oregan Health & Science University of Portland, Portalnd, Oregan, U.S.A.)
17:45	-- Audience Vote --
	Innovation
17:47	What is the next big thing in cardiac revascularisation? » Gary Ansel (Riverside Methodist Hospital, Columbus, Ohio, USA)
17:55	What is the next big thing in Electophysiological cardiac disease management? » Brendan O'Cochlain (Galway Clinic, Galway, Ireland)
18:00	First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo coronary artery lesions » Davide Capodanno (Ferrarotto Hospital, University of Catania, Catania, Italy)
18:15	Session 7: Disruptive Techologies & Innovative Solutions An introduction to new devices and pipeline technologies from world-leaders in the MedTech Sector
	What's New Out There?
18:15	The Uniballoon: Cage Moulding Catherter: Engineer » Wolfgang Meichelboeck (Pentenried, Germany)
18:20	The Uniballoon: Cage Moulding Catherter: Clinician » Venkatesh Raimiah (ARIZONA HEART INSTITUTE, USA.)
18:25	RHEOS Trial. Harnessing the carotid sinus barorecptor effect to treat refractory hypertension: Engineer » Ralf Velden (CVRx Inc., Germany)
18:30	RHEOS Trial. Harnessing the carotid sinus barorecptor effect to treat refractory hypertension: Clinician » Karl A Illig (University of Rochester, Rochester, New York, USA)
18:35	Multilayer stent technology: Engineer » Olivier Despalle De Bearn (Western Vascular Institute)
18:40	Branch graft technology: Clinician » Jacques Bleyn (Antwerp Blood Vessel Center, Belgium)
18:45	Branch graft technology: Engineer » Hajo Huckfeld (Gore Medical, Flagstaff, Arizona, USA)
18:50	Is the optimal topical hemostatic agent available for surgical intervention? » Katarina Björses (Vascular Center Malmö-Lund, Malmö University Hospital, Malmö, Sweden.), Jan Holst (Vascular Center Malmö-Lund, Malmö University Hospital, Malmö, Sweden.)
	A Different Perspective
18:55	Lessons Learned from conflict. How to save life and limb under the most terrifying of circumstances » Norman M. Rich (Bethesda, Maryland and Washington, District of Columbia, USA)
19:20	Adjournment Day One
Friday, 25th June
07:00	Session 8: Future Perspectives on Carotid Artery Intervention Can technology overcome the shortcomings of CAS technology: Debates and unique insights into future innovations.
	Level One Evidence: Are Rcts Applicable To Contemporary Carotid Practice?
07:00	Carotid Imaging and Surgery in view of the new recent trials and needs for future studies. » Jose Fernandes E Fernandes (Faculty of Medicine, University of Lisbon, Lisbon, Portugal)
	Debate 1:
07:05	Filter-protected CAS is more dangerous and associated with more procedure related complications than unfiltered CAS » Sherif Sultan (Western Vascular Institute)
07:10	Carotid Filters are as necessary as seat-belts and failure to use one puts the patients at enhanced risk of stroke » Gary Ansel (Riverside Methodist Hospital, Columbus, Ohio, USA)
07:15	-- Audience Vote --
	Debate 2:
07:17	Transcervical approach for CAS is safer and avoids the multiple pitfalls in the arch » Fotis Markatis (Laikon Hospital, University of Athens, Athens, Greece)
07:22	Transfemoral CAS offers long-term benefit and restenosis rates which are comparable to CEA » Mark Eskandari (Northwestern Memorial Hospital, Chicago, Illinois, USA)
07:27	-- Audience Vote --
	Debate 3:
07:29	Experience is the key is successful CAS » Klaus Mathias (Direktor der Radiologischen Klinik, Klinikum Dortmund, Germany)
07:34	Experience does not guarantee success for CAS: Lessons learned from RCTs » Sumaira MacDonald (Freeman Hospitals, Newcastle, UK)
07:39	-- Audience Vote --
	Debate 4:
07:41	Plaque echoluceny is the best indicator for procedure success according to protection device and learning curve » Giorgio M. Biasi (University of Milan-Bicocca, Milan, Italy)
07:46	Low GSM is not correlated to stroke risk » Gianmarco De Donato (University of Siena, Siena, Italy ), Carlo Setacci (University of Siena, Siena, Italy )
07:51	-- Audience Vote --
	Debate 5:
07:53	Carotid Intervention is superior to best medical treatment in patients with asymptomatic disease and stenosis above 60% » Peter A Schneider (Hawaii Permanente Medical Group, Honolulu, Hawaii)
07:58	Effect of exercise and statins on carotid artery stenosis: Intervention is not warranted in asymptomatic patients » John Kakisis (Athens University Medical School, Athens, Greece), Christos Liapis (Athens University Medical School, Athens, Greece)
08:03	-- Audience Vote --
08:05	-- Panel Sum-up --
	Current Clinical Standards
	Debate 6:
08:10	What does the SVS recommend for CEA? » Mark Eskandari (Northwestern Memorial Hospital, Chicago, Illinois, USA)
08:15	What does the ESVS recommend for CEA? » John Kakisis (Athens University Medical School, Athens, Greece), Christos Liapis (Athens University Medical School, Athens, Greece)
08:20	USA v Europe: Who has got it right? » Frank Veith (New York University School of Medicine, New York, USA)
08:25	-- Audience Vote --
08:27	Session 9: Trials and Tribulations of Thoracic Technologies Controveries and future projections among the diverse pathologies of the thoracic aorta.
	Debate 1:
08:27	The use of chimney and snorkel grafts in the aortic arch are universally applicable and offer a satisfactory solution especially in the emergency setting » Frank Criado (Union Memorial/MedStar Health)
08:32	Durability issues with Fenestrated and Chimney Grafts in the aortic arch make these a questionable long-term solution. Branched graft technology will eliminate the need for chimney grafts » Jacques Bleyn (Antwerp Blood Vessel Center, Belgium)
08:37	-- Audience Vote --
	Debate 2:
08:39	The Endovascular Specialist is well-equipped to deal with even the most challenging of aortic arches. » Mark Farber (University of North Carolina, Chapel Hill, North Carolina)
08:44	Hybrid Aortic Repair is a superior option. Endovascular technology is under-developed and will not survive in the long term in this high-pressure environment » Alan Lumsden (Methodist DeBakey Heart and Vascular Center)
08:49	-- Audience Vote --
	Debate 3:
08:51	Good risk patients are best served by endovascular technology. Device development has overcome limitations to the application of endografts in all pathologies » Jan Brunkwall (University of Cologne, Cologne, Germany)
08:56	Long term durability issues render endografts experimental especially in young and good risk patients: Open repair remains the gold standard » Hazim Safi (Memorial Hermann Hospital, Houston, Texas)
09:01	-- Audience Vote --
09:03	-- Panel Sum-up --
	A Look To The Future
09:08	Progress towards standard off-the-shelf branched components for TAAA and arch repair. » Timothy A Chuter (University of California, San Francisco, San Francisco, California)
09:13	Multi-layer Stents the new paradigm in TAAA repair » Mitchell Henry (The Ohio State University Columbus, USA)
	Tips And Tricks
09:18	Aortic arch anomalies are more common than you think: Case examples and treatment strategies » Frank Criado (Union Memorial/MedStar Health)
09:23	Early experience with cTAG » Jan Brunkwall (University of Cologne, Cologne, Germany)
09:28	Session 10: Pushing the Envelope with Endovascular Techniques for AAA Debates on Real-life clinical scenarios, pararenal aortic repair and a insight into current and future innovations
	Debate 1:
09:28	Hostile neck anatomy in endovascular aortic aneurysm repair is an independent adverse predictor for adverse outcome using modular devices. These aneurysms are best repaired using an open technique » Ali Aburahma (Robert C. Byrd Health Sciences Center, Charleston, West Virginia, USA)
09:33	Pararenal endovascular aortic repair is the superior to open repair and affords the most clinically efficacious and cost-effective outcome » Sherif Sultan (Western Vascular Institute)
09:38	-- Audience Vote --
	Debate 2:
09:40	A bifurcated device utilizing anatomical fixation is best equipped to deal with hostile neck anatomy and reduce migration risk. A look at the IntuiTrak System. » Venkatesh Ramaiah (ARIZONA HEART INSTITUTE, USA.)
09:45	Modular commercially available devices which are specifically built for short and angulated neck are a superior option in this anatomy. A look at the Endurant system » Vincent Riambau (University of Barcelona, Hospital Clinic, Barcelona, Spain)
09:50	-- Audience Vote --
	Debate 3:
09:52	Fenestrated and branched technology is the most clinically efficacious option for endovascular repair of pararenal aortas. They are worth the wait! » Timothy A Chuter (University of California, San Francisco, San Francisco, California)
09:57	Visceral chimney stenting during EVAR-offer a superior alternative to fenestrated/branched endograft that is more readily available with enhanced cost-effectiveness » W. Anthony Lee (Division of Vascular Surgery and Endovascular Therapy, Gainesville, Florida)
10:02	-- Audience Vote --
	Debate 4:
10:04	Management of mycotic perivisceral aortic pathology with the use of cryopreserved allografts: A superior option in infected territories » Mark D Morasch (Northwestern Memorial Hospital, Chicago, Illinois, USA)
10:09	Mycotic perivisceral aortic pathology: There is always the option of endovascular autologous stenting with Palmaz covered vein graft » Timur Sarac (The Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio)
10:14	-- Audience Vote --
10:16	-- Panel Sum-up --
	A Look To The Future
10:21	Robotically assisted In-situ fenestrated stent grafting » Colin Bicknell (Imperial College London), Celia Riga (Imperial College London), Melvinder Basra (Imperial College London), Mohamad Hamady (Imperial College London), Nick Cheshire (Imperial College London)
10:26	New stents and new graft materials for TAA and AAA repair. » Timothy A Chuter (University of California, San Francisco, San Francisco, California)
	Tips And Tricks
10:31	Technique For Placement Of Large Palmaz Stent For Proximal Neck Problem During EVAR: What Balloon, Sheath And Precautions Are Needed? » Dieter Raithel (Medical Centre of Nuremberg, Nuremberg, Germany)
	Trainees Perspectives
10:36	Early experience with chimney thoracoabdominal endografts » Peader Waters (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
10:40	Incidence of concomitant malignancy in AAA: 8 year experience » Wael Tawfick (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
10:44	Long-term follow-up of AAA patients and factors determining sac shrinkage » John Byrne (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
10:49	Coffee Break
11:15	Session 11: Putting the best foot forward:Optimal Management for PAD Present and future insights into optimal management of lower limb arterial disease
	Debate 1:
11:15	Cardiliogists have a lot to teach us about below the knee disease: Experience gained in the heart can be translated to the tibial tree » Gary Ansel (Riverside Methodist Hospital, Columbus, Ohio, USA)
11:20	Vascular surgeons are more experienced in infragenicular disease and are better equipped to treat these unique vessels » Sherif Sultan (Western Vascular Institute)
11:25	-- Audience Vote --
	Debate 2:
11:27	Lyse and Lase to reduce thromboembolic complications during endo-revasculariztion of arterial occlusive disease. Results of over 600 inpatients » Sam Ahn (University Vascular Associates and DFW Vascular Group, Dallas, Texas)
11:32	Distal filters are clinically superior and more cost effective in the management of lower limb embolisation. » Ali Amin (Reading Hospital and Medical Center, Reading, Pennsylvania)
11:37	-- Audience Vote --
	Debate 3:
11:39	Subintimal angioplasty is a technical error not a first choice procedure » Gianmarco De Donato (University of Siena, Siena, Italy ), Carlo Setacci (University of Siena, Siena, Italy )
11:44	Subintimal angioplasty is an invaluable and cost-effective technique in experienced hands » Sherif Sultan (Western Vascular Institute)
11:49	-- Audience Vote --
	Debate 4:
11:51	RE-entry devices are a vital component of any interventionalist lower limb armamentarium » Ali Amin (Reading Hospital and Medical Center, Reading, Pennsylvania)
11:59	Re-entry devices: add nothing but cost to the management of CTOs » Amman Bolia (Leicester Royal Infirmary, Leicester, United Kingdom)
12:04	-- Audience Vote --
12:06	It is time to grasp the nettle? Endovascular interventions should be performed by surgeons not Interventional Radiologists » Martin Feeley (The Adelaide & Meath Hospital, Tallaght, Dublin )
12:11	All that is necessary for Successful revascularisation is a good guide wire and a lowly guiding catheter. New devices are only toys and an unjustified expense » Amman Bolia (Leicester Royal Infirmary, Leicester, United Kingdom)
12:16	There is always plan D for Limb Salvage » Sherif Sultan (Western Vascular Institute)
12:21	-- Panel Sum-up --
	Imagine This
	Debate 5:
12:26	Phase-contrast flow quantification - has doppler ultrasound met its match? » Derek Lohan (National University of Ireland, Galway)
12:32	Doppler ultrasound is an essential, cost-effective and stand alone tool for vascular intervention. Contrast adds unnecessary risk » Anil Hingorani (College of Medicine, SUNY Brooklyn, Brooklyn, New York)
12:37	-- Audience Vote --
	Novel Markers To Predict Outcome
12:39	Impaired Glucose control and the use of HbA1c as a predictor of adverse events in vascular patients » Marc R.h.m. Van Sambeek (Erasmus University & Catharina Hospital, Eindhoven, The Netherlands)
12:44	Lunch
13:30	Session 12: Renal Disease: from access to renal artery Debates on the latest controversies in renal artery revascularisation and management of renal patients requiring dialysis access
	Renal Artery Disease
	Debate 1:
13:30	Percutaneous renal artery stenting is safe even in patients with single functioning Kidneys » Mark Davies (Methodist DeBakey Heart and Vascular Center)
13:35	Renal Stenting is Not a Painless Technique: Selective Mistakes in Percutaneous Angioplasty for Arteriosclerotic Renal Artery Stenotic Disease » James Stanley (University of Michigan, Ann Arbor, USA), Jonathan Eliason (University of Michigan, Ann Arbor, USA), Enrique Criado (University of Michigan, Ann Arbor, USA)
13:40	-- Audience Vote --
	Av Access
	Debate 2:
13:42	Dialysis catheters are bad news » Mitchell Henry (The Ohio State University Columbus, USA)
13:47	Centros(TM) Central Venous Catheter for Dialysis » Stephen Ash (Clarian Arnett Health, Lafayette, Indiana)
13:52	-- Audience Vote --
	Debate 3:
13:54	Primary AV Fistulas are the Gold standard. Synthetic grafts increase the risk of infection and are associated with reduced patency » Peter Lawrence (Gonda Vascular Center, Los Angeles, California, USA)
13:59	Synthetic Grafts simplify the AVF procedure, broaden the scope of suitable patients and have acceptable long term patency: Lessons learned from the Rapidax Clinical Trial. The Case for Synthetic Grafts or When to Break the Rules in Vascular Access Surgery. » Samuel Wilson (University of California, Irvine, California, USA)
14:04	-- Audience Vote --
14:06	How can we improve renal access grafts: Will they ever realistically compare to native vessels? » Tim McGloughlin (University of Limerick, Ireland.), Michael Walsh (University of Limerick, Ireland.)
	Trainees Perspective
14:11	Primary non-synthetic AVFs: Are proximal AVF access procedures superior to distal access interventions? A 5-Year congruence scrutiny assessment study. » Nader Hamada (Western Vascular Institute)
14:15	Session 13: Cardiovascular Anti-ageing & Regenerative Medicine Introduction to cardiovascular anti-ageing medicine and metabolic cardiovascular disease with cutting-edge debates on stem cell therapies
	Stem Cell Therapies For Critical Limb Ischaemia
	Debate 1:
14:15	Therapeutic potential of endothelial progenitor cells » Tim O'Brien (University College Hospital, Galway, Ireland)
14:20	Stems cells have not worked to date: Will embryonic stem cells make a difference? » William Pearce (Northwestern Memorial Hospital, Chicago, Illinois, USA)
14:25	-- Audience Vote --
	Cardiovascular Anti-ageing
14:27	Cardiovascular Antiageing: Can we role back the years? YES WE CAN! » Sherif Sultan (Western Vascular Institute)
14:32	Epigenomics and Vascular Disease » Venkatesh Ramaiah (ARIZONA HEART INSTITUTE, USA.)
14:42	Nutritional Supplementation for Carotid Artery Disease » Cliff Shearman (Southampton University Hospitals NHS Trust, United Kingdom)
14:47	Statin use in patients with diabetes and their role in new onset diabetes » Dimitri P Mikhailidis (Royal Free & University College School of Medicine, London, UK)
14:52	Optimal approaches to achieving lower LDL-C targets » Philippe Brudi (Merck & co)
	Trainees Perspective
14:57	Does statin adversely affect glycaemic control in non-obese Type 2 Diabetes Mellitus patients? A deplorable bona fide conscious clinical scenario! » Kamsila Pillay (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
15:01	A prospective study of the relevance of global vascular bed pathology in the pattern of management of vascular patients referred to a vascular tertiary referral centre. The clinical implications of presence of asymptomatic vascular pathology for outcome in peripheral arterial disease (PVD), abdominal aortic aneurysm (AAA) and carotid (CAS) intervention. » Cindy Chua (Western Vascular Institute), Sherif Sultan (Western Vascular Institute)
15:05	Session 14: Disruptive Technologies & Innovative Solutions More cutting edge technology and futuristic designs
15:05	Medtronic » Scott Cook (Medtronic, Galway, Ireland)
15:10	Gore Medical » Hajo Huckfeld (Gore Medical, Flagstaff, Arizona, USA)
15:15	Cordis » John Lardner (Cordis)
15:20	Boston Scientific » Tony Vrba (Boston Scientific)
	Indigenous Companies
15:25	Endovenous Sub-adventitial stripping of the Great Saphenous Vein; The 21st Century graceful solution. » Marto Hoary (Embricon Limited, NUIG innovation centre, Galway Ireland), Sherif Sultan (Western Vascular Institute)
15:30	The Cosmopolitan Chameleon. A multi-dimensional device for the future » Niamh Hynes (Western Vascular Institute)
	What Do The Bioengineers Have In The Pipeline?
15:35	Development of Tissue Lined Stents » Timur Sarac (The Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio), Frank Veith (New York University School of Medicine, New York, USA), Albrecht Kramer (The Cleveland Clinic and New York University, Cleveland, Ohio, USA)
15:40	Modified Surfaces to Capture Endothelial Progenitor Cells for Venous applications » Dusan Pavcnik (Oregan Health & Science University of Portland, Portalnd, Oregan, U.S.A.), Monica Hinds (Oregan Health & Science University of Portland, Portalnd, Oregan, U.S.A.)
15:45	Where are we with percutaneous endovenous valve technology? » Dusan Pavcnik (Oregan Health & Science University of Portland, Portalnd, Oregan, U.S.A.)
15:50	Coffee Break
16:15	Session 15: The Future Provision of Cardiovascular Therapies A frank discussion on the training, service development, industry interaction and medico-legal issues
	Innovation In The Management And Structure Of Vascular Services
16:15	Reconfiguration of vascular service. Is it a disaster or a luxury that we cannot afford? » Simon Cross (Waterford Regional Hospital, Waterford, Ireland)
16:20	Ten years late but still on track to declare our vascular independence » Jerry Goldstone (University Hospitals Case Medical Center, Cleveland, Ohio, USA)
16:25	Variations in Vascular Training across the globe: Has anyone got it right? » John Kakisis (Athens University Medical School, Athens, Greece), Christos Liapis (Athens University Medical School, Athens, Greece)
16:30	Royal College of Surgeons of England views on Vascular Training » Cliff Shearman (Southampton University Hospitals NHS Trust, United Kingdom)
	Debate 1:
16:35	Has patient focused care gone too far and instilled a culture of "easy-suing"? Who cares for the carer? » Simon Cross (Waterford Regional Hospital, Waterford, Ireland)
16:40	Medico-legal systems are in place for the protection of the patient. If physicians provide quality care and abide by clinical standards they have nothing to fear » O William Brown (Scottsdale, Arizona)
16:45	-- Audience Vote --
	Bio-convergence: How Can We Bring All Parties On Board?
16:47	A successful future for Vascular Specialist extends beyond Device design. How can we manage our future and move forward as a sector. Bioconvergence » Sherif Sultan (Western Vascular Institute)
16:52	What role does the Smart hospital have to play in bioconvergence and how can we work with industry and science to speed up its implication? » James Sheehan (Western Vascular Institute)
16:57	How do we best serve the patient? Has our relationship with industry been mismanaged. How to work together to enhance standards of care without breaching ethics » O William Brown (Scottsdale, Arizona)
	Breaking News
17:02	Endovascular treatment of chronic cerebrospinal venous insufficiency in the management of multiple sclerosis » Paolo Zamboni (University of Ferrara, Ferrara, Italy)
	Key Note Speaker
17:12	A glimpse into the future from a visionary pioneer » Edward Diethrich (Medical Director, Arizona Heart Institute & Hospital, USA)
17:25	Adjournment

Terms & Conditions | Privacy Policy | Disclaimer | Accessibility | Contact Us